These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Combined androgen blockade: the gold standard for metastatic prostate cancer. McLeod DG; Crawford ED; DeAntoni EP Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up. Akaza H; Homma Y; Usami M; Hirao Y; Tsushima T; Okada K; Yokoyama M; Ohashi Y; Aso Y; BJU Int; 2006 Sep; 98(3):573-9. PubMed ID: 16925756 [TBL] [Abstract][Full Text] [Related]
5. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer]. Tsukamoto S; Akaza H Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study. Ueno S; Namiki M; Fukagai T; Ehara H; Usami M; Akaza H Int J Urol; 2006 Dec; 13(12):1494-500. PubMed ID: 17118024 [TBL] [Abstract][Full Text] [Related]
7. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153 [TBL] [Abstract][Full Text] [Related]
8. Screening and hormonal therapy of localized prostate cancer shows major benefits on survival. Labrie F Cancer J; 2000 Apr; 6 Suppl 2():S182-7. PubMed ID: 10803834 [TBL] [Abstract][Full Text] [Related]
9. Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer. Abrahamsson PA; Anderson J; Boccon-Gibod L; Schulman C; Studer UE; Wirth M Eur Urol; 2005 Dec; 48(6):900-5. PubMed ID: 16257109 [TBL] [Abstract][Full Text] [Related]
11. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience. DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987 [TBL] [Abstract][Full Text] [Related]
12. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR; Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313 [TBL] [Abstract][Full Text] [Related]
13. Current treatment of advanced prostate cancer. Ismail M; Gomella LG Tech Urol; 1997; 3(1):16-24. PubMed ID: 9170220 [TBL] [Abstract][Full Text] [Related]
14. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals. Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106 [TBL] [Abstract][Full Text] [Related]
15. Endocrine therapy for prostate cancer. Damber JE Acta Oncol; 2005; 44(6):605-9. PubMed ID: 16165920 [TBL] [Abstract][Full Text] [Related]